False-positive ELISA reactions for the hepatitis C virus and the human immunodeficiency virus after anti-influenzal vaccination
Ioniţă, E.; Lupulescu, E.; Alexandrescu, V.; Chiriţă, C.; Bălteanu, M.; Neguţ, A.E.
Bacteriologia Virusologia Parazitologia Epidemiologia 40(3-4): 249-252
1995
ISSN/ISBN: 1220-3696 PMID: 8640012 Document Number: 441663
Possible appearance of ELISA false-positive results for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) after vaccination against influenza was studied on 402 volunteers before, and 30 and 90 days after that. Our results prove that influenza vaccine can sometimes induce false-positive ELISA for HCV, but not for HIV. Their frequency is relatively small--0.96% in 10-20-years-old group and 3.1% in over 60 years age, while in 3-6 years age there were not registered this kind of reactions. The surveillance of individual ELISA-positive cases over time proves that cross-reacting antibodies HCV raised after vaccination against influenza are present only in second sera, that means 30 days after vaccination, but these antibodies disappeared 90 days later.
Document emailed within 1 workday
Related Documents
Kline, M.W.; Lewis, D.E.; Hollinger, F.B.; Reuben, J.M.; Hanson, L.C.; Kozinetz, C.A.; Dimitrov, D.H.; Rosenblatt, H.M.; Shearer, W.T. 1994: A comparative study of human immunodeficiency virus culture, polymerase chain reaction and anti-human immunodeficiency virus immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection Pediatric Infectious Disease Journal 13(2): 90-94Lopez, N.A.; Jacobson, R.H. 1989: False-positive reactions associated with anti-mouse activity in serotests for feline leukemia virus antigen Journal of the American Veterinary Medical Association 195(6): 741-746
Sungkanuparph, S.; Vibhagool, A.; Manosuthi, W.; Kiertiburanakul, S.; Atamasirikul, K.; Aumkhyan, A.; Thakkinstian, A. 2004: Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study Journal of the Medical Association of Thailand 87(11): 1349-1354
Kazi, A.M.; Shah, S.A.; Jenkins, C.A.; Shepherd, B.E.; Vermund, S.H. 2010: Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan International Journal of Infectious Diseases: Ijid: Official Publication of the International Society for Infectious Diseases 14(Suppl 3): E60-E66
Calderón, G.M.; González-Velázquez, F.; González-Bonilla, C.R.; Novelo-Garza, B.ár.; Terrazas, J.J.; Martínez-Rodríguez, M.L.; Cortés-Márquez, S.R.; Blanco-Flores, J.P.; Rodríguez-Rodríguez, A.; Del Campo, M.A.; Cortés-Gómez, R.; Mejía-Bocanegra, M.G. 2009: Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico Transfusion 49(10): 2200-2207
Chung, D.C.; Ko, Y.C.; Chen, C.J.; Chen, E.R.; Wu, C.C.; Wu, P.S. 1989: Seroepidemiology of hepatitis B virus, hepatitis D virus, and human immunodeficiency virus infections among parenteral drug abusers in southern Taiwan Journal of Medical Virology 28(4): 215-218
Machado, A.A.; Hirsch, I.; Figueiredo, J.F.; Martinez, R.; de Freitas-Silva, G.; Chermann, J.C.; Covas, D.T. 1996: Occurrence of false positives in tests with synthetic peptides for the analysis of antibodies against the human immunodeficiency virus type 2 (HIV-2) in Brazilian patients infected with the human immunodeficiency virus type 1 (HIV-1) Revista da Sociedade Brasileira de Medicina Tropical 29(6): 615-617
Ruzibakiev, R.; Kato, H.; Ueda, R.; Yuldasheva, N.; Hegay, T.; Avazova, D.; Kurbanov, F.; Zalalieva, M.; Tuichiev, L.; Achundjanov, B.; Mizokami, M. 2001: Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in uzbekistan Intervirology 44(6): 327-332
Kania, D.; Sangaré, L.; Sakandé, J.; Koanda, A.; Nébié, Y.K.; Zerbo, O.; Combasséré, A.W.; Guissou, I.P.; Rouet, F.ço. 2009: A new strategy to improve the cost-effectiveness of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood donations in sub-Saharan Africa: a pilot study in Burkina Faso Transfusion 49(10): 2237-2240
Franke, M.F.; Stulac, S.N.; Rugira, I.H.; Rich, M.L.; Bucyibaruta, J.B.; Drobac, P.C.; Iyamungu, G.; Bryant, C.M.; Binagwaho, A.; Farmer, P.E.; Mukherjee, J.S. 2011: High human immunodeficiency virus-free survival of infants born to human immunodeficiency virus-positive mothers in an integrated program to decrease child mortality in rural Rwanda Pediatric Infectious Disease Journal 30(7): 614-616
Devi, K.S.; Singh, N.B.; Singh, H.L.; Singh, Y.M. 2009: Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users Journal of the Indian Medical Association 107(3): 144; 146-147
Koyanagi, A.; Humphrey, J.H.; Ntozini, R.; Nathoo, K.; Moulton, L.H.; Iliff, P.; Mutasa, K.; Ruff, A.; Ward, B.; Chidawanyika, H.; Hargrove, J.; Mahomva, A.I.; Majo, F.; Malaba, L.C.; Mbizvo, M.T.; Mzengeza, F.; Ndhlovu, M.; Piwoz, E.; Propper, L.; Rambanepasi, P.; Ruff, A.J.; Tavengwa, N.; Zijenah, L.S.; Zunguza, C.D.; Zvandasara, P. 2011: Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy Pediatric Infectious Disease Journal 30(1): 45-51
Kidangazhiayathmana, A. 2011: Is Kerala remaining low prevalent in human immunodeficiency virus by accident? a study of risk factors in acquiring human immunodeficiency virus infection in patients attending Anti-retroviral treatment clinic Indian Journal of Dermatology Venereology and Leprology 77(6): 729
Bassa, A.; Villalonga, C.; Parras, F.; Salvà, F.; Altés, J.; Salas, A. 1989: Infection caused by the human immunodeficiency virus, hepatitis B virus and delta virus in homosexual males Medicina Clinica 93(13): 490-492
Roux, P.; Fugon, L.; Winnock, M.; Salmon-Céron, D.; Lacombe, K.; Sogni, P.; Spire, B.; Dabis, F.ço.; Carrieri, M.P. 2012: Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users Addiction 107(1): 152-159
Pontzer, C.H.; Yamamoto, J.K.; Bazer, F.W.; Ott, T.L.; Johnson, H.M. 1997: Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau Journal of Immunology 158(9): 4351-4357
Panlilio, A.L.; Shapiro, C.N.; Schable, C.A.; Mendelson, M.H.; Montecalvo, M.A.; Kunches, L.M.; Perry, S.W.; Edwards, J.R.; Srivastava, P.U.; Culver, D.H. 1995: Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group Journal of the American College of Surgeons 180(1): 16-24
Pivert, A.; Payan, C.; Lunel, F.; C, E.R.T. A. 2004: Comparaison des cinétiques de l'ARN et de l'antigène de capside du virus de l'hépatite C dans le suivi thérapeutique des patients co-infectés par le virus de l'hépatite C et le virus de l'immunodéficience humaine, traités par bithérapie interféron-ribavirine, dans le cadre du protocole RIBAVIC - Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol Pathologie et Biologie 52(9): 522-528
Caredda, F.; Antinori, S.; Coppin, P.; Parravicini, C.; Vago, L.; Moroni, M. 1991: The influence of human immunodeficiency virus infection on acute and chronic HBsAg-positive hepatitis Progress in Clinical and Biological Research 364: 365-375
Iroezindu, M.O.; Daniyam, C.A.; Agbaji, O.O.; Isa, E.S.; Okeke, E.N.; Imade, G.E. 2013: Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria Journal of Infection in Developing Countries 7(12): 951-959